Strategic Investment Castle Creek Biosciences recently secured a significant $75 million royalty financing from Ligand Pharmaceuticals, indicating strong investor confidence and potential for expansion in their regenerative medicine portfolio.

Funding Momentum Having raised over $113 million in preferred stock financing and receiving ongoing investments, the company demonstrates substantial financial backing to accelerate gene therapy development and pipeline growth, offering opportunities for strategic partnerships.

Clinical Progress As a late-clinical stage company launching pivotal trials for severe skin and connective tissue disorders, Castle Creek presents sales prospects in early-access programs, clinical collaborations, and specialized medical device or treatment partnerships.

Innovative Technology Leveraging proprietary research based on fibroblasts for personalized gene therapies, Castle Creek’s cutting-edge approach creates opportunities to introduce complementary products, diagnostics, or supporting technology solutions.

Key Collaborations Partnership with Mayo Clinic showcases the company’s focus on rare diseases, paving the way for expanding clinical research collaborations and co-developing targeted therapies with institutions and specialized research centers.